Organic Active Ingredients TRIZ Cases

Low-activity, poorly druggable ferroptosis inhibitors motivate phenothiazine compounds with stronger inhibition and good cardiac safety.

Novel Formula I compounds target wild-type c-KIT kinase while limiting off-target signaling and CNS side effects in mast cell disorders.

Benzimidazole dimers act as STING agonists or antagonists, regulating type I interferon production for immune activation or suppression.

Multiple anhydrous, hydrated, and salt forms support stable pralsetinib compositions for consistent oral dosage development.

Disulfide linkers respond to tumor-cell glutathione, keeping SN-38 stable in normal cells and releasing it selectively.

Current KRAS G12C cancer treatments lack effective inhibitors; heteroaryl compounds are varied to selectively inhibit the mutant protein.

Crystalline diaminopyrimidine forms address poor solubility, dissolution, stability, and bioavailability through defined XRPD and DSC/TGA profiles.

Hot-melt extrusion combines telmisartan, meglumine, and polymer to form an amorphous dispersion for faster dissolution.

HDAC inhibitor payloads use antibody-linked structures to improve solid-tumor delivery while increasing plasma stability and cellular internalization.

Unchecked coronavirus replication is addressed with 5-amino phthalazinedione, which reduces viral load for treatment or prophylaxis.

Short-lived ERT clears Gb3 but leaves fibrosis progression; combining agalsidase-β with TGF-β inhibitors targets both limits.

Existing DYRK2 inhibitors show weak activity; benzothiazole pyrimidineamine structures tune potency and kinase selectivity.

Polysorbate and polyoxyl 40 stearate form nanomicelles that improve enavogliflozin eye-drop stability and intraocular exposure.

This case links (5R)-5-hydroxytriptolide with NF-κB and CD4+ T-cell inhibition to control AIDS immune activation with low cytotoxicity.

A formulation combining prebiotic oligosaccharides with beta-casein boosts beneficial bacteria and suppresses pathogens in infant gut microbiota.

Replacing silica carriers with sugar-based excipients helps tablets retain unstable active ingredients while preserving permeability and rapid disintegration.

Extensive deoxygenation adds equipment and time; heated dissolution, nitrogen cooling, and cysteine stabilization support paracetamol shelf-life.

New pyrrole compounds target fungal infections while changing molecular structure to address resistance and human CYP inhibition.

FFF printing builds the capsule shell while a separate dispenser fills the core, supporting customized dosage forms and improved drug stability.

A single pullwire bends one applicator to multiple sinus, nasal, ear, and throat targets while the fixed handle improves ergonomics.

Controlled crystallization of Asciminib mesylate targets solid-form stability and processing needs while supporting bioavailability optimization.

Cold atmospheric plasma transfers RONS into a hydrogel for localized cancer-cell killing while supporting bone tissue regeneration.

Arnica helenalin and flavonoids provide anti-inflammatory and antioxidant activity, while sodium hyaluronate supports lubrication for dry eye.

Intramolecular tricyclic benzotriazole derivatives inhibit Keap1 and activate Nrf2, offering potential antioxidant and therapeutic benefits for renal disease.

Changing substituents on a fused-piperidine scaffold targets rapid 5-HT2A-mediated antidepressant effects while avoiding hallucinogenic side effects.

IVL peptides and vitamin D receptor agonists improve skin barrier integrity and support atopic dermatitis treatment.

Linker composition and AR-binding substituents are varied to maintain receptor degradation while improving solubility and metabolic stability.

Variable absorption can make corneal neovascularization treatment inconsistent; naphthylurea eye drops provide targeted ocular delivery.

Selective 5-HT2A modulation with reduced 5-HT2B agonism supports non-hallucinogenic, non-cardiotoxic options for at-home psychological disorder treatment.

See how AMBMP analogs activate CaMKII and metabolic pathways to increase muscle mass, function, and oxidative capacity in muscular dystrophy.

Non-canonical TERT inhibition sensitizes cancer cells to genotoxic therapy while reducing treatment resistance and enhancing immune responses.

Novel spiro aromatic compounds target SHP2’s non-catalytic region to sustain its self-inhibiting state with strong activity at low concentrations.

ABP compounds with IL-2 and IL-15 or IL-18 sustain γδ T-cell growth, improving purity and yield from smaller blood samples.

Fusogenic nanoparticles address low cell penetration by encapsulating active agents for protection from biological degradation.

See how porous resorbable pouches secure implants through tissue ingrowth while degrading naturally without surgical removal.

Low cell permeability and nuclease degradation limit siRNA delivery; an ionic liquid supports skin penetration and stability for topical IL-23 inhibition.

Chelating agents bind transition metals while stabilizers limit degradants, helping preserve epinephrine effectiveness during storage.

Inhaled dry powder esketamine bypasses first-pass metabolism to reach therapeutic plasma levels while limiting systemic metabolites and adverse effects.

Bridging cereblon and target proteins enables ubiquitination and proteasomal degradation while addressing difficult protein-protein interaction surfaces.

Relacorilant lowers an elevated neutrophil-to-lymphocyte ratio alongside cancer treatment, supporting stronger treatment response and prognosis.

Alternating fields prime M0 or M2 macrophages toward M1 before antibiotics, strengthening immune response and potentially lowering drug doses and infection duration.

Fluid-bed granulation converts brittle ipatasertib into flowable granules, reducing lamination during high-speed tableting.

Selective HDAC6 inhibition uses 1,3,4-oxadiazole homophthalimide compounds to limit class I HDAC-related fatigue and nausea.

Structural optimization tunes lipophilicity, molecular weight, and functional groups to improve RORγ modulator potency.

A non-aqueous glycerin vehicle supports oral amlodipine delivery while maintaining formulation stability and dose uniformity.

Separate Panax, rutin, and Ginkgo formulations lack synergy; a solid lipid sol-gel carrier co-delivers them for improved bioavailability.

Acidifying the polymeric film to pH 1.5–5.0 helps stabilize tryptamines, extend shelf life, and support mucosal absorption.

Defined substituents and stereochemistry help balance FASN inhibition with specificity for cancer, metabolic, and autoimmune conditions.

After ocular surgery, chondroitin sulfate eye drops cushion the ocular surface and relieve pain or discomfort during recovery.

Applying a small-molecule analgesic over paraspinal skin routes it toward the DRG, targeting pain transmission without systemic exposure.

Potassium osmate oxidation of steroid substrates enables high purity estetrol production, resolving crystallization bottlenecks in pharmaceutical manufacturing.

A pressurized aerosol system delivers nicotine free base using specific solvent ratios to generate fine droplets for pulmonary absorption.

Combining PAC-1 with BRAF inhibitors directly activates procaspase-3 to induce cancer cell death.

Segmenting therapy with a CRF1 antagonist reduces ACTH-driven hormone levels, minimizing metabolic adverse effects from high-dose glucocorticoids.

N-(3-heteroarylaryl)-4-arylarylcarboxamides target aberrant hedgehog signaling to improve treatment specificity for basal cell carcinoma.

Coatable microparticles granulate onto drug-containing hollow cores to form controlled release layers.

A prefilled glass syringe tip features a 1.7 mm internal channel diameter designed for reversible attachment to needleless connectors.

Compounds concurrently inhibit DNA gyrase and topoisomerase IV, preventing resistance emergence from single mutations.

A biphasic ceramic carrier delivers sustained antibiotic release to treat deep bone infections.

Anti-CD44 antibodies block drug efflux pathways to improve tumor treatment reliability while reducing ascites volumes.

Compounds like 5,3'-dihydroxyflavone inhibit steroid hormone receptor binding to ELK1, resolving inadequate treatment efficacy for hormone-dependent cancers.

Increasing antioxidant protein expression inhibits oxidative stress to prevent progressive vision loss from retinitis pigmentosa.

Substituted heterocyclic compounds inhibit bacterial DNA gyrase, addressing antibiotic resistance and toxicity issues in existing treatments.

Stabilizing spinach thylakoid extracts in lipid carriers reduces inflammatory biomarkers and symptom scores while avoiding steroid resistance side effects.

Tariquidar blocks P-glycoprotein efflux pumps to increase intracellular alkaloid accumulation, reducing systemic toxicity in metastatic cancers.

Viscosity-lowering agents reduce polysaccharide solution thickness for easier injection.

Kinase inhibitors form reversible covalent bonds with cysteine residues to reduce toxicity and immunogenic problems caused by irreversible electrophilic agents.

Segmenting receptor subtypes resolves the trade-off between anti-inflammatory efficacy and gastrointestinal toxicity.

Cyclic bridging heteroaryl compounds treat resistant helminth infections by broadening activity spectrum while reducing treatment frequency.

Prostaglandin analogues address the trade-off between ocular pressure control and hair growth stimulation by targeting multiple biological pathways.

Amorphous dasatinib salts overcome poor aqueous solubility of crystalline forms by forming composite materials that resist crystallization.

A ketamine transdermal patch delivers sustained antidepressant effects through a drug-in-adhesive layer.

Modified antisense oligonucleotides target intron 1 regions to promote exon 2 retention and enhance GAA enzyme activity.

Phosphomimetic CHIP variants inhibit toxic protein accumulation by mimicking phosphorylation states, addressing proteotoxicity in myocardial ischemia.

Rifaximin in polymorphic form beta provides gastric resistance and intestinal release, eliminating heavy enteric coatings to reduce tablet weight.

Lipid nanoparticle delivery of siRNA removes mutant and wild-type transthyretin protein, arresting neuropathy progression.

Substituted benzene compounds inhibit EZH2 activity, reducing aberrant H3-K27 methylation to treat lymphoma and leukemia.

A biodegradable hydrogel implant disperses axitinib to maintain therapeutic drug levels in the eye for extended periods.

A variant RNAi molecule with a guide region bulge reduces off-target silencing while maintaining huntingtin protein suppression.

Direct encapsulation of blended Orlistat avoids complex extrusion steps, ensuring chemical stability while reducing manufacturing costs.

Covalent crosslinking maintains hydrogel cohesion and scavenges free radicals, preventing fragmentation that triggers inflammatory reactions.

GalNAc moiety conjugates to oligonucleotides for specific hepatocyte binding.

Pectin shields zein nanoparticles from pH and ionic strength changes, preventing aggregation during digestion.

Tilted crystal conjugates prevent dissection during insertion, improving drug release efficiency for treating restenosis.

Glycosyl hesperetin promotes perspiration while suppressing core body temperature rise, enabling safe daily ingestion for infants and the elderly.

Chimeric compounds link IRAK4 binding moieties to degradation signaling elements for targeted protein destruction.

Block-distributed acetylated polyglucosamine activates the cGAS-STING pathway, resolving limited cell entry issues of cyclic dinucleotide analogues.

Zinc-containing vaginal hydrogel reduces recurrent vulvovaginal candidiasis by altering the local microenvironment to inhibit fungal growth.

A nutraceutical composition uses carrot extract and plant inhibitors to capture dietary lipids.

Genetically modified mastocytoma cells generate high-purity heparin with potent anticoagulant activity, eliminating disease risks from animal-derived sources.

Three-dimensional bridged bicyclic compounds restore synaptic function during acute oxidative stress events.

Oxygen barrier coatings eliminate harmful antioxidants while preventing oxidative degradation of simvastatin and ezetimibe.

Optimized binder ratios resolve the contradiction between tablet hardness and dissolution rate, achieving low friability and rapid drug release.

Segmenting bruceolides with cleavable moieties resolves the contradiction between high cancer cell killing rates and toxicity to healthy cells.

A self-amplifying RNA platform incorporates specific RdRP-binding sites to enable direct enzymatic amplification without DNA templates.

A pharmaceutical formulation containing tomatidine, rapamycin, and xylitol modifies the gut microbiome to enhance bone strength.

Segmented coatings isolate doxylamine and pyridoxine to prevent degradation interactions while maintaining controlled release profiles.

Dry tableting via roller compaction preserves the crystal form stability of TNO155 API while improving tablet tensile strength and densification.

5α-androst-3β,5,6β-triol mitigates high mortality rates by reducing cerebral hemorrhage volume and improving neurosensory outcomes.

A therapeutic liposome encapsulates doxorubicin within a specialized bilayer structure.

Segmented modular structures optimize STING agonist efficacy to resolve insufficient immune response induction in antiviral therapies.

An immunoglobulin binding factor reagent binds to the Fc region of antibodies to form targeted immune complexes.

Quaternized chitosan polymers inhibit coronavirus replication through electrostatic and hydrophobic interactions with viral spike proteins.

Crystalline nanocellulose protects hyaluronic acid from oxidative breakdown, extending therapeutic duration.

Covalent bonding of agents to external vesicle surfaces enables deep skin penetration without structural disruption.

Segmented fused bicyclic compounds inhibit GPR91 to treat diverse physiological effects while managing structural complexity.

A tipifarnib intravenous formulation utilizes hydroxypropyl-beta-cyclodextrin to solubilize the drug for infusion.

Rapid injection rates minimize needle clogging and tissue irritation while ensuring effective drug delivery.

N-acetylated D-cysteine maintains vancomycin stability in aqueous solution by reducing degradation products.

A composite nutritional beverage delivers specific amino acids and antioxidants to support brain health.

Simvastatin induces BMP-2 expression to repair cartilage defects while preventing osteosclerosis and bone spur formation.

Neopinone isomerase converts morphinan precursors into codeinone and morphinone, reducing unwanted by-product accumulation to enhance production yield.

Administering mixed allergen compositions reduces Th2 proliferation and IgE levels while increasing IgG4 to prevent food allergies.

Eliminating chromatographic purification through two-phase solvent extraction simplifies ozanimod manufacturing while maintaining high intermediate purity.

Inhibiting ARID1A-containing BAF complexes provides broad-spectrum antiviral activity against coronavirus infections.

A composition combining daidzein with taxifolin or 3-O-methyl quercetin inhibits alpha-glucosidase activity through synergistic flavonoid interaction.

Targeted micelles solve poor water solubility by using composite materials to enhance tumor accumulation while reducing systemic toxicity.

Competitive inhibitor peptides block the pro-PrP-FLNa binding interface, reducing cancer cell adhesion and metastasis.

Screening compounds that selectively activate mTORC2 to enhance glucose uptake, avoiding Akt stimulation side effects like cancer promotion.

Gingerenone A prodrugs cleave in vivo to release active compounds, addressing limited bioavailability of direct senotherapeutics.

An anti-GPR20 antibody-drug conjugate targets malignant cells via receptor-mediated endocytosis.

PDE7 inhibitors boost intracellular cAMP to enhance dopamine signaling, reducing levodopa-induced dyskinesias and extending symptom relief duration.

Dendrimer carriers attach taxanes via diacid linkers, eliminating Cremophor EL excipients that cause hypersensitivity.

Azaquinazoline compounds inhibit atypical protein kinase C by targeting unique regulatory domains, overcoming isoform selectivity challenges in cancer therapy.

Engineered soluble CD23 polypeptides sequester IgE to prevent receptor binding, resolving side effects from existing allergy therapies.

A pharmaceutical compound accelerates liver regeneration by stimulating hepatocyte proliferation.

Substituted phenyl oxazolone compounds target the Cullin4-Cereblon E3 ubiquitin ligase complex to degrade specific proteins.

A single-chain nanoparticle terpolymer forms 20 nm micelles to overcome renal clearance and achieve high tumor accumulation of anticancer agents.

Segmented analysis of syndecan and hyaluronic acid levels resolves early detection accuracy versus disease-specific prediction capability.

Terminal vinylphosphonate nucleotide resists enzymatic degradation while maintaining RISC loading efficiency.

Dual-action bicyclic compounds reduce lysophosphatidic acid levels by simultaneously inhibiting autotaxin and carbonic anhydrase II enzymes.

Segmenting drugs into distinct compartments resolves scalability and reproducibility issues while reducing toxicity through controlled sequential loading.

A metered dose inhaler vaporizes cannabis plant material to deliver pharmacologically active agents through controlled heating.

Spray drying produces a stable dry powder that slows dissolution and extends nasal residence time.

L-oxiracetam enhances brain ATP and acetylcholine synthesis to promote wakefulness in coma patients.

Amorphous solid dispersion of triptolide with excipients overcomes poor water solubility to enhance bioavailability and therapeutic efficacy.

Formula I compounds target the Hedgehog pathway to suppress cancer proliferation while preserving normal tissue homeostasis.

Leucine and acetyl-leucine treat migraine prophylaxis by reducing aura symptoms and headache intensity where conventional therapies remain inadequate.

Imidazopyrimidine compounds bind the EED subunit of the Polycomb Repressive Complex 2 to inhibit enzymatic activity.

Amino-oxazine compounds regulate beta-secretase activity through specific molecular binding.